eFFECTOR Therapeutics, Inc.
US ˙ OTCPK

Introdução

Esta página fornece uma análise abrangente do histórico conhecido de negociações internas de Peter Svennilson. Insiders são oficiais, diretores ou investidores significativos em uma empresa. É ilegal para insiders realizarem negociações em suas próprias empresas baseados em informações específicas, não públicas. Isso não significa que seja ilegal para eles realizarem qualquer negociação em suas próprias empresas. No entanto, eles devem reportar todas as negociações à SEC através de um Formulário 4. Apesar dessas restrições, pesquisas acadêmicas sugerem que insiders - em geral - tendem a superar o mercado em suas próprias empresas.

Rentabilidade Média de Negociação

A rentabilidade média de negociação é o retorno médio de todas as compras de mercado abertas feitas pelo insider nos últimos três anos. Para calcular isso, examinamos cada compra de mercado aberto, não planejada, feita pelo insider, excluindo todas as negociações que foram marcadas como parte de um plano de negociação 10b5-1. Em seguida, calculamos o desempenho médio dessas negociações ao longo de 3, 6 e 12 meses, fazendo a média de cada uma dessas durações para gerar uma métrica de desempenho final para cada negociação. Finalmente, fazemos a média de todas as métricas de desempenho para calcular uma métrica de desempenho para o insider. Esta lista inclui apenas insiders que fizeram pelo menos três negociações nos últimos dois anos.

Se a rentabilidade de negociação deste insider é "N/A", então o insider ou não fez quaisquer compras de mercado aberto nos últimos três anos, ou as negociações que eles fizeram são muito recentes para calcular uma métrica de desempenho confiável.

Frequência de Atualização: Diariamente

Veja a lista dos negociantes internos mais rentáveis.

Empresas com Posições Internas Reportadas

As declarações à SEC indicam que Peter Svennilson reportou posses ou negociações nas seguintes empresas:

Ativo Título Últimas Posições Reportadas
US:TNYA / Tenaya Therapeutics, Inc. 10% Owner 0
10% Owner 1,319,164
US:SRZN / Surrozen, Inc. 10% Owner 1,016,658
US:RAPT / RAPT Therapeutics, Inc. 10% Owner 0
US:NGM / NGM Biopharmaceuticals, Inc. 10% Owner 1,000
US:ORIC / ORIC Pharmaceuticals, Inc. 10% Owner 74
US:EFTR / eFFECTOR Therapeutics, Inc. 10% Owner 4,309,329
US:NRIX / Nurix Therapeutics, Inc. 10% Owner 48,406
US:RVMD / Revolution Medicines, Inc. Director 1,775,236
10% Owner 99,155
US:GRTS / Gritstone bio, Inc. Director, 10% Owner 8,570
US:IMDZ / Immune Design Corp. 10% Owner 0
US:RCUS / Arcus Biosciences, Inc. 10% Owner 0
Como Interpretar os Gráficos

Os gráficos a seguir mostram o desempenho das ações dos a ativos ubsequentes a cada transação de mercado aberto, não planejada feita por Peter Svennilson. Transações não planejadas são negociações que não foram feitas como parte de um plano de negociação 10b5-1. O desempenho das ações é representado como mudança percentual cumulativa no preço das ações. Por exemplo, se uma transação interna foi feita em 1 de janeiro de 2019, o gráfico mostrará a mudança percentual diária da segurança até o dia presente. Se o preço da ação passasse de $10 para $15 durante este período, a mudança percentual cumulativa no preço das ações seria de 50%. Uma mudança no preço de $10 para $20 seria de 100%, e uma mudança no preço de $10 para $5 seria de -50%.

Ultimamente, estamos tentando determinar quão estreitamente as negociações do interno correlacionam-se a retornos excessivos (positivos ou negativos) no preço da ação para ver se o interno está cronometrando suas transações para lucrar com informações internas. Considere a situação onde um interno estava fazendo isso. Nesta situação, esperaríamos (a) retornos positivos após compras, ou (b) retornos negativos após vendas. No caso de (a), o gráfico de COMPRA mostraria uma série de curvas ascendentes, indicando retornos positivos após cada transação de compra. No caso de (b), o gráfico de VENDA mostraria uma série de curvas descendentes, indicando retornos negativos após cada transação de venda.

No entanto, isso sozinho não é suficiente para tirar conclusões. Se, por exemplo, o preço da ação da empresa estivesse em uma escalada não cíclica ao longo de muitos anos, então esperaríamos que todos os gráficos pós-compra tivessem uma inclinação ascendente. Da mesma forma, declínios não cíclicos ao longo de muitos anos resultariam em gráficos pós-negociação inclinados para baixo. Nenhum desses gráficos sugeriria atividade de negociação interna.

O indicador mais forte seria uma situação em que o preço da ação fosse extremamente cíclico, e houvesse sinais positivos no gráfico de COMPRA e gráficos negativos no gráfico de VENDA. Esta situação seria altamente sugestiva de um interno que estava cronometrando transações para sua vantagem financeira.

Compras Internas EFTR / eFFECTOR Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

EFTR / eFFECTOR Therapeutics, Inc. Insider Trades
Vendas Internas EFTR / eFFECTOR Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

EFTR / eFFECTOR Therapeutics, Inc. Insider Trades
Compras Internas NRIX / Nurix Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

NRIX / Nurix Therapeutics, Inc. Insider Trades
Vendas Internas NRIX / Nurix Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

NRIX / Nurix Therapeutics, Inc. Insider Trades
Compras Internas ORIC / ORIC Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

ORIC / ORIC Pharmaceuticals, Inc. Insider Trades
Vendas Internas ORIC / ORIC Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

ORIC / ORIC Pharmaceuticals, Inc. Insider Trades
Compras Internas RCUS / Arcus Biosciences, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

RCUS / Arcus Biosciences, Inc. Insider Trades
Vendas Internas RCUS / Arcus Biosciences, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

RCUS / Arcus Biosciences, Inc. Insider Trades
Compras Internas RVMD / Revolution Medicines, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

RVMD / Revolution Medicines, Inc. Insider Trades
Vendas Internas RVMD / Revolution Medicines, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

RVMD / Revolution Medicines, Inc. Insider Trades
Compras Internas SRZNW / Surrozen, Inc. - Equity Warrant - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
2026-01-20 SRZN COLUMN GROUP III GP, LP 8,484 19.5999 8,484 19.5999 166,286 106 34.1300 123,274 74.13
2026-01-20 SRZN COLUMN GROUP III GP, LP 9,568 19.5999 9,568 19.5999 187,532
2026-01-16 SRZN COLUMN GROUP III GP, LP 1,204 20.0000 1,204 20.0000 24,080
2026-01-16 SRZN COLUMN GROUP III GP, LP 1,358 20.0000 1,358 20.0000 27,160
2026-01-15 SRZN COLUMN GROUP III GP, LP 5,590 19.8890 5,590 19.8890 111,180
2026-01-15 SRZN COLUMN GROUP III GP, LP 6,303 19.8890 6,303 19.8890 125,360
2026-01-14 SRZN COLUMN GROUP III GP, LP 2,596 19.9883 2,596 19.9883 51,890
2026-01-14 SRZN COLUMN GROUP III GP, LP 2,927 19.9883 2,927 19.9883 58,506
2026-01-13 SRZN COLUMN GROUP III GP, LP 5,861 19.8041 5,861 19.8041 116,072
2026-01-13 SRZN COLUMN GROUP III GP, LP 6,609 19.8041 6,609 19.8041 130,885
2026-01-06 SRZN COLUMN GROUP III GP, LP 7,097 19.8872 7,097 19.8872 141,139
2026-01-06 SRZN COLUMN GROUP III GP, LP 8,003 19.8872 8,003 19.8872 159,157

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

SRZNW / Surrozen, Inc. - Equity Warrant Insider Trades
Vendas Internas SRZNW / Surrozen, Inc. - Equity Warrant - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

SRZNW / Surrozen, Inc. - Equity Warrant Insider Trades
Compras Internas TNYA / Tenaya Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em EFTR / eFFECTOR Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

TNYA / Tenaya Therapeutics, Inc. Insider Trades
Vendas Internas TNYA / Tenaya Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em EFTR / eFFECTOR Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
2026-02-25 TNYA COLUMN GROUP III GP, LP 1,649,281 0.5624 1,649,281 0.5624 927,556 6 0.5500 -20,450 -2.20
2026-02-25 TNYA COLUMN GROUP III GP, LP 1,862,545 0.5624 1,862,545 0.5624 1,047,495
2026-02-24 TNYA COLUMN GROUP III GP, LP 309,228 0.6153 309,228 0.6153 190,268
2026-02-24 TNYA COLUMN GROUP III GP, LP 349,212 0.6153 349,212 0.6153 214,870
2026-02-23 TNYA COLUMN GROUP III GP, LP 143,709 0.5972 143,709 0.5972 85,823
2026-02-23 TNYA COLUMN GROUP III GP, LP 162,291 0.5972 162,291 0.5972 96,920
2026-02-20 TNYA COLUMN GROUP III GP, LP 245,965 0.6149 245,965 0.6149 151,244
2026-02-20 TNYA COLUMN GROUP III GP, LP 277,769 0.6149 277,769 0.6149 170,800
2026-02-11 TNYA COLUMN GROUP III GP, LP 1,905,115 0.6808 1,905,115 0.6808 1,297,002
2026-02-11 TNYA COLUMN GROUP III GP, LP 2,151,458 0.6808 2,151,458 0.6808 1,464,713
2026-02-10 TNYA COLUMN GROUP III GP, LP 161,422 0.8161 161,422 0.8161 131,736
2026-02-10 TNYA COLUMN GROUP III GP, LP 182,295 0.8161 182,295 0.8161 148,771

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

TNYA / Tenaya Therapeutics, Inc. Insider Trades
Histórico de Negociações Insider

Esta tabela mostra a lista completa de negociações insider realizadas por Peter Svennilson conforme divulgadas para a Comissão de Valores Mobiliários (SEC).

Data do Arquivo Data da Transação Formulário Ticker Ativo Código 10b5-1 Ações Ações Restantes Variação
Percentual
Preço
da Ação
Valor
da Transação
Valor
Restante
2026-02-26 2026-02-25 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -1,862,545 0 -100.00 0.56 -1,047,495
2026-02-26 2026-02-25 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -1,649,281 0 -100.00 0.56 -927,556
2026-02-26 2026-02-24 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -349,212 1,862,545 -15.79 0.62 -214,870 1,146,024
2026-02-26 2026-02-24 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -309,228 1,649,281 -15.79 0.62 -190,268 1,014,803
2026-02-24 2026-02-23 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -162,291 2,211,757 -6.84 0.60 -96,920 1,320,861
2026-02-24 2026-02-23 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -143,709 1,958,509 -6.84 0.60 -85,823 1,169,622
2026-02-24 2026-02-20 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -277,769 2,374,048 -10.47 0.61 -170,800 1,459,802
2026-02-24 2026-02-20 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -245,965 2,102,218 -10.47 0.61 -151,244 1,292,654
2026-02-12 2026-02-11 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -2,151,458 2,651,817 -44.79 0.68 -1,464,713 1,805,357
2026-02-12 2026-02-11 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -1,905,115 2,348,183 -44.79 0.68 -1,297,002 1,598,643
2026-02-12 2026-02-10 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -182,295 4,803,275 -3.66 0.82 -148,771 3,919,953
2026-02-12 2026-02-10 4 TNYA Tenaya Therapeutics, Inc.
Common Stock
S - Sale -161,422 4,253,298 -3.66 0.82 -131,736 3,471,116
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
P - Purchase 630,881 1,319,164 91.66 18.00 11,355,858 23,744,952
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
P - Purchase 49,556 148,840 49.91 18.00 892,008 2,679,120
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
P - Purchase 1,437,323 4,312,139 50.00 18.00 25,871,814 77,618,502
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 688,283 688,283
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 3,785 99,284 3.96
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 47,898 95,499 100.62
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 44,249 47,601 1,320.08
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 110,928 2,874,816 4.01
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 1,403,568 2,763,888 103.18
2026-02-09 2026-02-06 4 EIKN Eikon Therapeutics, Inc.
Common Stock
C - Conversion 1,296,629 1,360,320 2,035.81
2026-01-20 2026-01-20 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 9,568 1,016,658 0.95 19.60 187,532 19,926,395
2026-01-20 2026-01-20 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 8,484 900,292 0.95 19.60 166,286 17,645,633
2026-01-20 2026-01-16 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 1,358 1,007,090 0.14 20.00 27,160 20,141,800
2026-01-20 2026-01-16 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 1,204 891,808 0.14 20.00 24,080 17,836,160
2026-01-20 2026-01-15 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 6,303 1,005,732 0.63 19.89 125,360 20,003,004
2026-01-20 2026-01-15 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 5,590 890,604 0.63 19.89 111,180 17,713,223
2026-01-15 2026-01-14 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 2,927 999,429 0.29 19.99 58,506 19,976,887
2026-01-15 2026-01-14 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 2,596 885,014 0.29 19.99 51,890 17,689,925
2026-01-15 2026-01-13 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 6,609 996,502 0.67 19.80 130,885 19,734,825
2026-01-15 2026-01-13 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 5,861 882,418 0.67 19.80 116,072 17,475,494
2026-01-08 2026-01-06 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 8,003 989,893 0.82 19.89 159,157 19,686,200
2026-01-08 2026-01-06 4 SRZN Surrozen, Inc./DE
Common Stock
P - Purchase 7,097 876,557 0.82 19.89 141,139 17,432,264
2024-12-23 2024-12-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -1,599,417 0 -100.00
2024-12-23 2024-12-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -1,352,008 50,000 -96.43
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
J - Other 1,000 1,000
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -44,000 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -15,000 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -100,000 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -100,000 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -1,298,908 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -1,298,908 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -2,265,758 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -968,990 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -858,035 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -11,103,333 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -90,442 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -2,650,177 0 -100.00
2024-04-08 2024-04-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -949,862 0 -100.00
2023-11-17 2023-11-16 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 5,840 949,862 0.62 0.62 3,627 589,959
2023-11-17 2023-11-15 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 16,791 944,022 1.81 0.71 11,880 667,896
2023-02-01 2023-01-31 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 176,730 927,231 23.55 5.00 883,403 4,634,857
2023-02-01 2023-01-30 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 7,542 750,501 1.02 5.00 37,707 3,752,205
2023-01-25 2023-01-23 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 9,900 742,959 1.35 5.00 49,494 3,714,349
2023-01-23 2023-01-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 500 733,059 0.07 5.00 2,498 3,662,363
2023-01-23 2023-01-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 37,639 732,559 5.42 5.00 188,105 3,661,037
2023-01-17 2023-01-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 5,378 694,920 0.78 4.95 26,603 3,437,491
2023-01-12 2023-01-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 209,000 689,542 43.49 4.76 994,840 3,282,220
2023-01-12 2023-01-10 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 100,070 480,542 26.30 4.84 484,519 2,326,688
2022-12-14 2022-12-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 300 380,472 0.08 4.98 1,493 1,893,495
2022-11-23 2022-11-22 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 4,330 380,172 1.15 5.00 21,646 1,900,518
2022-11-23 2022-11-21 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 35,997 375,842 10.59 5.00 179,942 1,878,759
2022-11-07 2022-11-04 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 35,058 339,845 11.50 4.72 165,320 1,602,573
2022-11-07 2022-11-03 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 104,090 304,787 51.86 4.99 519,107 1,520,003
2022-10-31 2022-10-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 76,877 200,697 62.09 4.86 373,638 975,428
2022-10-27 2022-10-26 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 72,774 123,820 142.57 4.85 353,041 600,676
2022-10-27 2022-10-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 51,046 51,046 4.75 242,387 242,387
2022-06-13 2022-06-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 32,477 90,442 56.03 13.50 438,440 1,220,967
2022-06-13 2022-06-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 951,684 2,650,177 56.03 13.50 12,847,734 35,777,390
2022-06-06 2022-06-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,129 57,965 1.99 13.03 14,715 755,475
2022-06-06 2022-06-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 33,071 1,698,493 1.99 13.03 431,024 22,136,969
2022-06-02 2022-06-01 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 3,036 56,836 5.64 13.45 40,834 764,444
2022-06-02 2022-06-01 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 88,964 1,665,422 5.64 13.45 1,196,566 22,399,926
2022-06-02 2022-05-31 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,040 53,800 3.94 13.47 27,470 724,460
2022-06-02 2022-05-31 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 59,766 1,576,458 3.94 13.47 804,797 21,228,268
2022-05-31 2022-05-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 89 51,760 0.17 13.45 1,197 696,239
2022-05-31 2022-05-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,621 1,516,692 0.17 13.45 35,256 20,401,479
2022-05-31 2022-05-26 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 667 51,671 1.31 13.49 9,000 697,223
2022-05-31 2022-05-26 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 19,534 1,514,071 1.31 13.49 263,582 20,430,117
2022-05-27 2022-05-25 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 63 42,189 0.15 12.45 785 525,460
2022-05-27 2022-05-25 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 1,837 1,236,261 0.15 12.45 22,880 15,397,507
2022-05-26 2022-05-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,429 51,004 2.88 13.43 19,198 685,234
2022-05-26 2022-05-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 41,863 1,494,537 2.88 13.43 562,425 20,078,955
2022-05-26 2022-05-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 588 49,575 1.20 13.37 7,860 662,719
2022-05-26 2022-05-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17,240 1,452,674 1.20 13.37 230,464 19,419,346
2022-05-25 2022-05-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 538 42,126 1.29 12.00 6,457 505,600
2022-05-25 2022-05-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 15,776 1,234,424 1.29 12.00 189,345 14,815,680
2022-05-25 2022-05-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 338 41,588 0.82 12.50 4,225 519,821
2022-05-25 2022-05-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 9,898 1,218,648 0.82 12.50 123,718 15,232,247
2022-05-23 2022-05-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 628 48,987 1.30 13.48 8,464 660,227
2022-05-23 2022-05-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 18,406 1,435,434 1.30 13.48 248,069 19,346,205
2022-05-23 2022-05-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 682 48,359 1.43 13.25 9,040 640,984
2022-05-23 2022-05-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 19,984 1,417,028 1.43 13.25 264,882 18,782,281
2022-05-19 2022-05-18 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,067 47,677 4.53 13.20 27,292 629,522
2022-05-19 2022-05-18 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 60,583 1,397,044 4.53 13.20 799,932 18,446,429
2022-05-19 2022-05-17 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,939 45,610 6.89 13.42 39,433 611,954
2022-05-19 2022-05-17 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 86,110 1,336,461 6.89 13.42 1,155,346 17,931,431
2022-05-17 2022-05-16 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,094 42,671 2.63 12.90 14,114 550,520
2022-05-17 2022-05-16 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 32,072 1,250,351 2.63 12.90 413,777 16,131,403
2022-05-17 2022-05-13 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 4,269 41,577 11.44
2022-05-17 2022-05-13 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 125,096 1,218,279 11.44
2022-05-13 2022-05-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17 37,308 0.05 11.81 201 440,447
2022-05-13 2022-05-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 485 1,093,183 0.04 11.81 5,726 12,905,791
2022-05-13 2022-05-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,728 37,291 7.89 11.62 31,702 433,362
2022-05-13 2022-05-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 79,945 1,092,698 7.89 11.62 929,049 12,698,353
2022-05-13 2022-05-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 88 34,563 0.26 11.85 1,043 409,478
2022-05-13 2022-05-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,564 1,012,753 0.25 11.85 30,376 11,998,389
2022-05-13 2022-05-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,657 34,475 8.35 11.23 29,827 387,009
2022-05-13 2022-05-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 77,866 1,010,189 8.35 11.23 874,108 11,340,180
2022-05-12 2022-05-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 41,250 41,250 10.67 440,199 440,199
2022-05-12 2022-05-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 1,208,750 1,208,750 10.67 12,899,176 12,899,176
2022-05-11 2022-05-10 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,032 31,818 3.35 11.36 11,727 361,567
2022-05-11 2022-05-10 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 30,233 932,323 3.35 11.36 343,556 10,594,546
2022-05-11 2022-05-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,745 30,786 9.79 10.79 29,627 332,270
2022-05-11 2022-05-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 80,430 902,090 9.79 10.79 868,073 9,736,167
2022-01-26 2022-01-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 19,791 28,041 239.89
2022-01-26 2022-01-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 579,910 821,660 239.88
2022-01-26 2022-01-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 8,250 8,250
2022-01-26 2022-01-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 241,750 241,750
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other 74 74
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other 86,716 103,341 521.60
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other 86,716 103,341 521.60
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other -287,702 0 -100.00
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other 287,702 287,702
2021-11-16 2021-11-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
J - Other -1,200,000 3,568,181 -25.17
2021-11-16 2021-11-12 4 ORIC Oric Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -16,625 0 -100.00
2021-11-16 2021-11-12 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
M - Exercise 16,625 16,625 16.00 266,000 266,000
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -625 6,875 -8.33
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -1,114 1,115 -49.98
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -7,500 15,000 -33.33
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -625 0 -100.00 34.94 -21,840
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
M - Exercise 625 625 19.30 12,062 12,062
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,114 0 -100.00 34.96 -38,951
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
M - Exercise 1,114 1,114 22.20 24,731 24,731
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,500 0 -100.00 34.48 -258,606
2021-09-29 2021-09-27 4 RAPT RAPT Therapeutics, Inc.
Common Stock
M - Exercise 7,500 7,500 28.27 212,025 212,025
2021-09-16 2021-09-15 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,720 0 -100.00 37.70 -177,957
2021-09-16 2021-09-15 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -12,939 4,720 -73.27 37.22 -481,634 175,694
2021-09-16 2021-09-15 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,400 0 -100.00 37.67 -165,762
2021-09-16 2021-09-15 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -11,476 4,400 -72.29 37.21 -427,066 163,741
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,926 0 -100.00 37.31 -109,158
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -32,211 2,926 -91.67 36.85 -1,187,066 107,831
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,496 35,137 -4.08 35.75 -53,477 1,256,028
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -10,807 17,659 -37.96 37.31 -403,261 658,942
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -42,151 28,466 -59.69 36.92 -1,556,046 1,050,851
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,700 70,617 -2.35 35.77 -60,814 2,526,196
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -25,351 15,876 -61.49 37.27 -944,844 591,706
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -29,634 41,227 -41.82 36.79 -1,090,143 1,516,614
2021-09-16 2021-09-14 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,400 70,861 -1.94 35.71 -49,990 2,530,241
2021-09-14 2021-09-13 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,788 36,633 -11.56 35.28 -168,942 1,292,577
2021-09-14 2021-09-13 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,726 72,261 -6.14 35.27 -166,692 2,548,739
2021-09-14 2021-09-13 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,803 72,317 -6.23 35.25 -169,309 2,549,218
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,231 41,421 -14.86 35.19 -254,494 1,457,808
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,320 76,987 -8.68 35.19 -257,572 2,708,980
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,187 77,120 -8.52 35.19 -252,940 2,714,169
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 48,652 48,652
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 84,307 84,307
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 84,307 84,307
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 72 163 79.12
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -279,710 0 -100.00
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 279,710 279,710
2021-09-14 2021-09-10 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -1,166,666 1,402,008 -45.42
2021-09-07 3 EFTR eFFECTOR Therapeutics, Inc.
Common Stock
4,309,329
2021-09-03 2021-09-02 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -18,556 0 -100.00 35.43 -657,469
2021-09-03 2021-09-02 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -18,545 0 -100.00 35.43 -657,083
2021-09-03 2021-09-01 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,064 18,556 -27.57 35.46 -250,484 657,981
2021-09-03 2021-09-01 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -8,805 25,620 -25.58 35.06 -308,681 898,173
2021-09-03 2021-09-01 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -8,976 18,545 -32.62 35.39 -317,674 656,335
2021-09-03 2021-09-01 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -6,904 27,521 -20.06 35.02 -241,753 963,684
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,100 0 -100.00 31.77 -225,532
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -4,318 7,100 -37.82 30.94 -133,602 219,680
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -3,463 34,425 -9.14 31.76 -109,978 1,093,273
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,200 37,888 -5.49 30.79 -67,740 1,166,606
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -3,486 34,425 -9.20 31.76 -110,707 1,093,252
2021-08-24 2021-08-24 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,300 37,911 -5.72 30.81 -70,853 1,167,875
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,100 11,418 -15.53 32.38 -68,005 369,750
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -12,354 13,518 -47.75 31.42 -388,123 424,692
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -8,204 25,872 -24.08 30.94 -253,856 800,555
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,007 40,088 -4.77 32.39 -65,012 1,298,555
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -13,623 42,095 -24.45 31.40 -427,810 1,321,930
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,278 55,718 -11.55 30.92 -225,026 1,722,728
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -2,200 40,211 -5.19 32.35 -71,168 1,300,786
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -12,969 42,411 -23.42 31.41 -407,373 1,332,185
2021-08-24 2021-08-23 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -7,605 55,380 -12.07 30.93 -235,198 1,712,721
2021-08-24 2021-08-20 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,670 34,076 -4.67 30.07 -50,222 1,024,774
2021-08-24 2021-08-20 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,429 62,996 -2.22 30.08 -42,985 1,894,932
2021-08-24 2021-08-20 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -1,440 62,985 -2.24 30.09 -43,327 1,895,086
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 35,746 35,746
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 64,425 64,425
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 64,425 64,425
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 91 91
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -208,403 0 -100.00
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other 208,403 208,403
2021-08-20 2021-08-18 4 RAPT RAPT Therapeutics, Inc.
Common Stock
J - Other -1,317,005 2,568,674 -33.89
2021-06-24 2021-05-28 4 RAPT RAPT Therapeutics, Inc.
Stock Option (right to buy)
A - Award 7,500 7,500
2021-06-17 2021-06-16 4 ORIC Oric Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 16,625 16,625
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 7,752 48,406 19.07
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 17,829 139,383 14.67
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 17,829 139,383 14.67
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other -49,689 0 -100.00
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 49,689 49,689
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other -1,000,000 989,000 -50.28
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 30,347 40,654 294.43
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 111,247 121,554 1,079.33
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 105,874 116,181 1,027.20
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other -438,338 0 -100.00
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 10,307 10,307
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 10,307 10,307
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 10,307 10,307
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other 438,338 438,338
2021-05-07 2021-05-05 4 NRIX Nurix Therapeutics, Inc.
Common Stock
J - Other -2,000,000 1,394,333 -58.92
2021-04-28 2021-04-28 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -53 1,775,236 0.00 42.50 -2,252 75,447,530
2021-04-28 2021-04-28 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -47 1,571,963 0.00 42.50 -1,998 66,808,428
2021-04-28 2021-04-27 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -12,371 1,775,289 -0.69 42.65 -527,659 75,721,224
2021-04-28 2021-04-27 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -10,955 1,572,010 -0.69 42.65 -467,263 67,050,785
2021-04-28 2021-04-26 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -28,101 1,787,660 -1.55 42.85 -1,204,027 76,594,795
2021-04-28 2021-04-26 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -24,883 1,582,965 -1.55 42.85 -1,066,147 67,824,352
2021-04-12 2021-04-09 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -13,101 1,815,761 -0.72 43.83 -574,162 79,577,178
2021-04-12 2021-04-09 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -11,600 1,607,848 -0.72 43.83 -508,379 70,465,225
2021-04-12 2021-04-08 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -24,518 1,828,862 -1.32 44.80 -1,098,507 81,940,516
2021-04-12 2021-04-08 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -21,710 1,619,448 -1.32 44.80 -972,697 72,557,910
2021-04-07 2021-04-07 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -14,825 1,853,380 -0.79 45.60 -676,087 84,522,468
2021-04-07 2021-04-07 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -13,128 1,641,158 -0.79 45.60 -598,696 74,844,190
2021-04-07 2021-04-06 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -20,949 1,868,205 -1.11 48.06 -1,006,847 89,789,295
2021-04-07 2021-04-06 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -18,551 1,654,286 -1.11 48.06 -891,594 79,507,963
2021-04-07 2021-04-05 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -9,661 1,889,154 -0.51 46.65 -450,732 88,138,102
2021-04-07 2021-04-05 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale X -8,554 1,672,837 -0.51 46.65 -399,085 78,045,876
2021-04-02 2021-03-31 4 RAPT RAPT Therapeutics, Inc.
Stock Option (right to buy)
A - Award 2,229 2,229 15.70 34,996 34,996
2021-02-19 2021-02-17 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
S - Sale -10,000 99,155 -9.16 36.95 -369,503 3,663,807
2020-12-16 2020-12-14 4 CNST CONSTELLATION PHARMACEUTICALS INC
Warrant (right to buy)
X - Other -30,107 0 -100.00
2020-12-16 2020-12-14 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
X - Other 30,107 2,584,957 1.18 1.55 46,666 4,006,683
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other 13,068 20,302 180.65
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other 46 46
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other -46,868 0 -100.00
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other 24,857 46,868 112.93
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other -530,365 1,898,815 -21.83
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other 22,011 22,011
2020-12-11 2020-12-09 4 RVMD Revolution Medicines, Inc.
Common Stock
J - Other -469,635 1,681,391 -21.83
2020-11-18 2020-11-16 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -1,075,133 2,429,180 -30.68 36.40 -39,134,841 88,422,152
2020-11-18 2020-11-16 4 RVMD Revolution Medicines, Inc.
Common Stock
S - Sale -952,023 2,151,026 -30.68 36.40 -34,653,637 78,297,346
2020-09-22 2020-09-22 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -608,000 3,835,679 -13.68 30.85 -18,756,800 118,330,697
2020-09-03 2020-09-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 27,595 1,827,025 1.53 17.67 487,604 32,283,532
2020-09-03 2020-09-01 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 36,494 1,799,430 2.07 17.64 643,754 31,741,945
2020-08-31 2020-08-28 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 26,135 1,762,936 1.50 17.89 467,555 31,538,925
2020-08-31 2020-08-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 36,359 1,736,801 2.14 17.79 646,827 30,897,690
2020-08-25 2020-08-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 100 1,700,442 0.01 18.00 1,800 30,607,956
2020-08-25 2020-08-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 11,024 1,700,342 0.65 17.96 197,991 30,538,142
2020-08-25 2020-08-21 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 7,321 1,689,318 0.44 17.97 131,558 30,357,044
2020-08-19 2020-08-17 4 RAPT RAPT Therapeutics, Inc.
Common Stock
S - Sale -538,654 4,443,679 -10.81 22.75 -12,254,378 101,093,697
2020-08-17 2020-08-17 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 6,425 1,681,997 0.38 17.89 114,943 30,090,926
2020-08-17 2020-08-14 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 37,993 1,675,572 2.32 17.49 664,498 29,305,754
2020-08-17 2020-08-13 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 19,895 1,637,579 1.23 17.89 355,922 29,296,288
2020-08-03 2020-07-30 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 732 1,617,684 0.05 17.99 13,169 29,102,135
2020-07-30 2020-07-28 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 4,105 1,616,952 0.25 17.99 73,849 29,088,966
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series D Preferred Stock
C - Conversion -686,274 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series D Preferred Stock
C - Conversion -686,274 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1,989,000 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1,836,000 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series A-2 Preferred Stock
C - Conversion -875,000 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Series A-1 Preferred Stock
C - Conversion -600,000 0 -100.00
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 686,274 686,274
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 686,274 686,274
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 1,989,000 1,989,000
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 1,836,000 3,394,333 117.82
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 875,000 1,558,333 128.05
2020-07-29 2020-07-28 4 NRIX Nurix Therapeutics, Inc.
Common Stock
C - Conversion 600,000 683,333 720.00
2020-07-28 2020-07-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 3,834 1,612,847 0.24 17.99 68,974 29,015,118
2020-07-28 2020-07-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 68,749 1,609,013 4.46 17.93 1,232,670 28,849,603
2020-07-23 2020-07-22 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 193 1,540,264 0.01 18.00 3,474 27,724,752
2020-07-23 2020-07-21 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -24,000 0 -100.00
2020-07-23 2020-07-21 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
M - Exercise 24,000 44,000 120.00 13.35 320,400 587,400
2020-07-23 2020-05-20 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 16,806 16,806
2020-07-23 2019-05-15 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 24,000 24,000
2020-07-23 2019-05-15 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 24,000 24,000
2020-07-23 3 NRIX Nurix Therapeutics, Inc.
Common Stock
166,666
2020-07-23 3 NRIX Nurix Therapeutics, Inc.
Common Stock
166,666
2020-07-23 3 NRIX Nurix Therapeutics, Inc.
Common Stock
166,666
2020-07-23 3 NRIX Nurix Therapeutics, Inc.
Common Stock
166,666
2020-06-19 2020-06-17 4 RVMD Revolution Medicines, Inc.
Stock Option (Right to Buy)
A - Award 25,318 25,318
2020-06-19 2020-06-17 4 RVMD Revolution Medicines, Inc.
Common Stock
A - Award 7,234 7,234
2020-06-19 2020-06-18 4 RAPT RAPT Therapeutics, Inc.
Stock Option (right to buy)
A - Award 22,500 22,500
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series D Preferred Stock
C - Conversion -151,515 0 -100.00
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series C Preferred Stock
C - Conversion -416,666 0 -100.00
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series B Preferred Stock
C - Conversion -625,000 0 -100.00
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series A Preferred Stock
C - Conversion -3,500,000 0 -100.00
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
C - Conversion 151,515 4,768,181 3.28
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
C - Conversion 416,666 4,616,666 9.92
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
C - Conversion 625,000 4,200,000 17.48
2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock
C - Conversion 3,500,000 3,575,000 4,666.67
2020-04-27 2020-04-23 4 ORIC Oric Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 16,625 16,625
2020-04-23 3 ORIC Oric Pharmaceuticals, Inc.
Common Stock
150,000
2020-04-23 3 ORIC Oric Pharmaceuticals, Inc.
Common Stock
150,000
2020-04-23 3 ORIC Oric Pharmaceuticals, Inc.
Common Stock
150,000
2020-04-09 2020-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 112,602 17,706,978 0.64 14.95 1,683,400 264,719,321
2020-04-07 2020-04-07 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 123,728 17,594,376 0.71 14.38 1,779,209 253,007,127
2020-04-07 2020-04-03 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 14,587 17,470,648 0.08 12.41 181,025 216,810,742
2020-04-02 2020-04-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 14,850 17,456,061 0.09 12.40 184,140 216,455,156
2020-04-02 2020-04-01 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 118,067 17,441,211 0.68 12.26 1,447,501 213,829,247
2020-04-02 2020-03-31 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 118,067 17,323,144 0.69 12.53 1,479,380 217,058,994
2020-03-25 2020-03-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,416 17,205,077 0.01 12.49 30,176 214,891,412
2020-03-25 2020-03-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 128,377 17,202,661 0.75 12.22 1,568,767 210,216,517
2020-03-25 2020-03-23 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 170,387 17,074,284 1.01 11.63 1,981,601 198,573,923
2020-03-23 2020-03-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 143,082 16,903,897 0.85 11.77 1,684,075 198,958,868
2020-03-23 2020-03-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 148,464 16,760,815 0.89 11.59 1,720,698 194,257,846
2020-03-23 2020-03-20 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
P - Purchase 5,539 6,051,376 0.09 23.15 128,228 140,089,354
2020-03-23 2020-03-19 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
P - Purchase 36,135 6,045,837 0.60 22.38 808,701 135,305,832
2020-03-06 2020-03-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 8,307 16,612,351 0.05 18.00 149,526 299,022,318
2020-03-04 2020-03-04 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 9,986 16,604,044 0.06 17.96 179,349 298,208,630
2020-03-04 2020-03-03 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 38,758 16,594,058 0.23 17.99 697,256 298,527,103
2020-03-04 2020-03-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 14,124 16,555,300 0.09 17.90 252,820 296,339,870
2020-02-28 2020-02-28 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 37,800 16,541,176 0.23 17.91 676,998 296,252,462
2020-02-28 2020-02-27 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 33,896 16,503,376 0.21 17.91 607,077 295,575,464
2020-02-28 2020-02-26 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 3,751 16,469,480 0.02 18.00 67,518 296,450,640
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series C Preferred Stock
C - Conversion -99,758 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series B Preferred Stock
C - Conversion -2,740,043 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Series A Preferred Stock
C - Conversion -5,137,583 0 -100.00
2020-02-18 2020-02-18 4 RVMD Revolution Medicines, Inc.
Common Stock
C - Conversion 7,977,384 7,977,384
2020-02-10 2020-02-06 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 44,900 16,465,729 0.27 15.96 716,604 262,793,035
2019-11-13 2019-11-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 15 16,420,829 0.00 12.00 180 197,049,948
2019-11-06 2019-11-04 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 8,409 16,420,814 0.05 11.99 100,824 196,885,560
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series C-2 Preferred Stock
C - Conversion -872,410 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series C-2 Preferred Stock
C - Conversion -872,410 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -8,724,100 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -4,362,050 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -7,000,000 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -14,781,963 0 -100.00
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 145,401 145,401
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 145,401 145,401
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 1,454,016 1,454,016
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
P - Purchase 625,000 4,982,333 14.34 12.00 7,500,000 59,787,996
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 727,008 4,357,333 20.03
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 1,166,666 3,630,325 47.36
2019-11-04 2019-11-04 4 RAPT RAPT Therapeutics, Inc.
Common Stock
C - Conversion 2,463,659 2,463,659
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-30 3 RAPT RAPT Therapeutics, Inc.
Common Stock
100,000
2019-10-24 2019-10-23 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,087 16,412,405 0.01 11.86 24,752 194,651,123
2019-10-24 2019-10-22 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,300 16,410,318 0.01 12.00 27,600 196,923,816
2019-10-21 2019-10-21 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 43,400 16,408,018 0.27 11.94 518,196 195,911,735
2019-10-21 2019-10-18 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 34,721 16,364,618 0.21 11.29 392,000 184,756,537
2019-10-21 2019-10-17 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 6,818 16,329,897 0.04 10.62 72,407 173,423,506
2019-10-16 2019-10-16 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 34,900 16,323,079 0.21 10.26 358,074 167,474,791
2019-10-16 2019-10-15 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 33,200 16,288,179 0.20 10.31 342,292 167,931,125
2019-10-16 2019-10-14 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 34,900 16,254,979 0.22 10.36 361,564 168,401,582
2019-10-11 2019-10-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17,724 16,220,079 0.11 10.57 187,343 171,446,235
2019-10-11 2019-10-10 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17,724 16,202,355 0.11 10.50 186,102 170,124,728
2019-10-11 2019-10-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17,724 16,184,631 0.11 10.26 181,848 166,054,314
2019-10-07 2019-10-03 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
P - Purchase 80,000 159,155 101.07 8.50 680,000 1,352,818
2019-10-07 2019-10-03 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
P - Purchase 1,331,764 6,009,702 28.47 8.50 11,319,994 51,082,467
2019-08-09 2019-08-09 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 152 16,166,907 0.00 13.99 2,126 226,175,029
2019-08-09 2019-08-08 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 12 16,166,755 0.00 13.98 168 226,011,235
2019-08-09 2019-08-07 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 224,500 16,166,743 1.41 14.00 3,143,000 226,334,402
2019-08-07 2019-08-06 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 310 15,942,243 0.00 13.96 4,328 222,553,712
2019-08-07 2019-08-05 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 5,824 15,941,933 0.04 13.98 81,400 222,814,021
2019-08-05 2019-08-02 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,782 15,936,109 0.01 13.97 24,898 222,660,909
2019-08-05 2019-08-01 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 2,600 15,934,327 0.02 13.98 36,346 222,749,144
2019-07-31 2019-07-30 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 8,855 15,931,727 0.06 13.91 123,195 221,650,152
2019-07-31 2019-07-29 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 19,201 15,922,872 0.12 13.58 260,727 216,213,494
2019-07-26 2019-07-26 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 30,059 15,903,671 0.19 13.59 408,634 216,200,865
2019-07-26 2019-07-25 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 30,753 15,873,612 0.19 13.37 411,294 212,295,274
2019-07-26 2019-07-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 29,054 15,842,859 0.18 13.51 392,502 214,027,519
2019-07-23 2019-07-23 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 30,760 15,813,805 0.19 13.35 410,535 211,057,367
2019-07-23 2019-07-22 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 30,760 15,783,045 0.20 13.54 416,337 213,623,514
2019-07-23 2019-07-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 6,222 15,752,285 0.04 13.99 87,043 220,366,591
2019-07-17 2019-07-16 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 3,900 15,746,063 0.02 13.86 54,055 218,245,157
2019-07-17 2019-07-15 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 16,188 15,742,163 0.10 13.69 221,547 215,445,669
2019-07-15 2019-07-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 21,014 15,725,975 0.13 13.88 291,765 218,344,155
2019-07-15 2019-07-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 10,870 15,704,961 0.07 13.87 150,752 217,805,822
2019-06-26 2019-06-24 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 12,240 15,694,091 0.08 13.78 168,650 216,242,602
2019-06-21 2019-06-21 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 3,763 15,681,851 0.02 14.03 52,789 219,992,847
2019-06-21 2019-06-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 15,400 15,678,088 0.10 13.86 213,385 217,238,723
2019-06-21 2019-06-19 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 15,214 15,662,688 0.10 13.91 211,674 217,916,544
2019-06-20 2019-06-19 4 GRTS Gritstone Oncology, Inc.
Stock Option (Right to Buy)
A - Award 8,570 8,570
2019-06-14 2019-06-14 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 10,760 15,647,474 0.07 14.00 150,687 219,133,485
2019-06-14 2019-06-13 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 11,500 15,636,714 0.07 14.13 162,508 220,963,969
2019-06-14 2019-06-12 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 7,500 15,625,214 0.05 14.00 104,989 218,729,558
2019-06-11 2019-06-11 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 10,900 15,617,714 0.07 13.83 150,718 215,950,817
2019-06-11 2019-06-07 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 12,600 15,606,814 0.08 13.66 172,176 213,263,992
2019-06-06 2019-06-06 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 12,600 15,594,214 0.08 13.40 168,884 209,017,047
2019-06-06 2019-06-04 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 12,600 15,581,614 0.08 13.39 168,764 208,700,138
2019-05-22 2019-05-20 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 50,000 15,569,014 0.32 13.50 675,000 210,181,689
2019-05-17 2019-05-15 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 24,000 24,000
2019-05-13 2019-05-10 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 17,923 15,519,014 0.12 13.85 248,234 214,938,344
2019-05-09 2019-05-07 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 57,000 15,501,091 0.37 14.10 803,700 218,565,383
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Series D Convertible Preferred Stock
C - Conversion -3,400,000 0 -100.00
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Series C Convertible Preferred Stock
C - Conversion -2,377,334 0 -100.00
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Series B Convertible Preferred Stock
C - Conversion -8,408,933 0 -100.00
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Series A Convertible Preferred Stock
C - Conversion -12,000,000 0 -100.00
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
C - Conversion 13,093,134 15,444,091 556.93
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 1,875,000 2,350,957 393.94 16.00 30,000,000 37,615,312
2019-04-10 2019-04-08 4 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 20,000 20,000 16.00 320,000 320,000
2019-04-03 3 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
951,914
2019-04-03 3 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
951,914
2019-04-03 3 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
951,914
2019-04-02 2019-04-02 4 IMDZ IMMUNE DESIGN CORP.
Common Stock
U - Other -6,642,942 0 -100.00 5.85 -38,861,211
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Series B Convertible Preferred Stock
C - Conversion -929,022 0 -100.00
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Series A Convertible Preferred Stock
C - Conversion -2,173,912 0 -100.00
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Common Stock
C - Conversion 3,102,934 3,102,934
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Series B Convertible Preferred Stock
C - Conversion -929,022 0 -100.00
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Series A Convertible Preferred Stock
C - Conversion -2,173,912 0 -100.00
2018-10-02 2018-10-02 4 GRTS Gritstone Oncology, Inc.
Common Stock
C - Conversion 3,102,934 3,102,934
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock
C - Conversion -20,000,000 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series E-1 Preferred Stock
C - Conversion -6,502,856 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series E Preferred Stock
C - Conversion -3,555,555 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series D Preferred Stock
C - Conversion -970,159 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -8,333,333 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -11,000,000 0 -100.00
2018-07-23 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
C - Conversion 4,666,888 4,677,939 42,230.46
2018-07-18 3 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
22,102
2018-07-18 3 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
22,102
2018-07-18 3 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock
22,102
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Series C Preferred Stock
C - Conversion -470,427 0 -100.00
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Series C Preferred Stock
C - Conversion -427,660 0 -100.00
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Series B Preferred Stock
C - Conversion -875,087 0 -100.00
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Series A Preferred Stock
C - Conversion -1,767,676 0 -100.00
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
C - Conversion 470,427 470,427
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
C - Conversion 427,660 3,070,423 16.18
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
C - Conversion 875,087 2,642,763 49.50
2018-03-19 2018-03-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
C - Conversion 1,767,676 1,767,676
2018-01-08 2018-01-04 4 IMDZ Immune Design Corp.
Stock Option (right to buy)
A - Award 12,500 12,500
2017-10-27 2017-10-27 4 IMDZ Immune Design Corp.
Common Stock
P - Purchase 2,681,000 2,681,000 4.10 10,992,100 10,992,100
2017-01-06 2017-01-04 4 IMDZ Immune Design Corp.
Stock Option (right to buy)
A - Award 10,000 10,000
2016-09-20 2016-09-20 4 IMDZ Immune Design Corp.
Common Stock
P - Purchase 800,000 800,000 6.25 5,000,000 5,000,000
2016-01-06 2016-01-04 4 IMDZ Immune Design Corp.
Stock Option (right to buy)
A - Award 9,300 9,300
2015-01-09 2015-01-07 4 IMDZ Immune Design Corp.
Stock Option (right to buy)
A - Award 9,300 9,300
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series C Preferred Stock
C - Conversion -428,134 0 -100.00
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series C Preferred Stock
X - Other 428,134 428,134
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series C Preferred Stock Warrant (right to buy)
X - Other -428,134 0 -100.00
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series C Preferred Stock
C - Conversion -856,269 0 -100.00
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series B Preferred Stock
C - Conversion -744,580 0 -100.00
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Series A Preferred Stock
C - Conversion -733,943 0 -100.00
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Common Stock
P - Purchase 399,016 3,161,942 14.44 12.00 4,788,192 37,943,304
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Common Stock
C - Conversion 428,134 2,762,926 18.34
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Common Stock
C - Conversion 856,269 2,334,792 57.91
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Common Stock
C - Conversion 744,580 1,478,523 101.45
2014-07-31 2014-07-29 4 IMDZ Immune Design Corp.
Common Stock
C - Conversion 733,943 733,943
P
Compra de mercado aberto ou privada de ativo não-derivativo ou derivativo
S
Venda de mercado aberto ou privada de ativo não-derivativo ou derivativo
A
Concessão, premiação, ou outra aquisição de ativos da empresa (como uma opção)
C
Conversão de derivativo
D
Venda ou transferência de ativos de volta para a empresa
F
Pagamento do preço de exercício ou responsabilidade fiscal utilizando parte dos ativos recebidos da empresa
G
Doação de ativos pelo ou para o insider
K
Swaps de capital e transações de hedge similares
M
Exercício ou conversão de ativo derivativo recebido da empresa (como uma opção)
V
Uma transação voluntariamente reportada no Formulário 4
J
Outro (acompanhado de uma nota explicativa descrevendo a transação)